Baird Maintains Outperform on Enovis, Lowers Price Target to $64
Baird analyst Jeffrey Johnson maintains Enovis (NYSE:ENOV) with a Outperform and lowers the price target from $68 to $64.
Enovis FY23 Outlook: EPS $2.15 – $2.30 Vs. $2.43 Estimate, Revenue Growth 5% – 6%
2023 Financial Outlook
Enovis also announced financial expectations for 2023. Revenue is expected to organically grow 5-6% from the prior year, with adjusted EBITDA of $255 to $265 million and adjusted earnings per
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Enovis Receives FDA Approval Of Patient Specific Instrumentation For STAR Ankle
Enovis Corporation (NYSE:ENOV), an innovation-driven medical technology company, announced that the U.S. Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System)
Enovis Q3 Adjusted EPS $0.59 Beats $0.48 Estimate, Sales $384.00M Beat $381.89M Estimate
Enovis (NYSE:ENOV) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.48 by 22.92 percent. This is a 63.58 percent decrease over earnings of $1.62 per share from the same
Wells Fargo Maintains Equal-Weight on Enovis, Lowers Price Target to $53
Wells Fargo analyst Vik Chopra maintains Enovis (NYSE:ENOV) with a Equal-Weight and lowers the price target from $60 to $53.
Jefferies Initiates Coverage On Enovis with Buy Rating, Announces Price Target of $60
Jefferies analyst Young Li initiates coverage on Enovis (NYSE:ENOV) with a Buy rating and announces Price Target of $60.
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.